To systematically study the role of DNA methylation in explaining the downstream effects of genetic variation, we analyzed genomewide genotype and DNA methylation in whole blood from 3,841 samples from five Dutch biobanks [9] [10] [11] [12] [13] (Fig. 1, Supplementary  Table 1 and Supplementary Note). We found cis methylation quantitative trait locus (meQTL) effects for 34.4% of all 405,709 CpGs tested (n = 139,566 at a CpG-level FDR of 5%, P ≤ 1.38 × 10 −4 ), typically with a short physical distance between the SNP and CpG (median distance = 10 kb; Supplementary Fig. 1 ). By regressing out the effect of the primary meQTL for each of these CpGs and repeating the cis-meQTL mapping, we observed up to 16 independent cis-meQTLs for each CpG site (Supplementary  Table 2 ), totaling 272,037 independent cis-meQTL effects. We found that few factors determine whether a CpG site shows a cis-meQTL effect other than variance in the methylation levels of the CpG site involved (Supplementary Figs. 2 and 3) . The proportion of variance in methylation explained by SNPs, however, is typically small (Supplementary Fig. 3b ). When accounting for this strong effect of CpG variation, we found only modest enrichments and depletions of cis-meQTL CpG sites in CpG island and genic
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We contrasted these modest functional enrichments to those of CpGs whose methylation levels correlated with gene expression in cis (that is, expression quantitative trait methylation (eQTM)) by Figure 2 Characterization of identified cis-and trans-meQTL and eQTM effects. (a-c) Over-or under-representation of CpGs in predicted chromatin states for cis-meQTLs (a), eQTMs (b) and trans-meQTLs (c). Gray bars reflect uncorrected enrichment; colored bars reflect enrichment after correction for factors influencing the likelihood of harboring a meQTL or eQTM, including methylation variability. Bar graphs show odds ratios; error bars, 95% confidence intervals. CGI, CpG island; TssA, active TSS; TssAFlnk, flanking active TSS; TxFlnk, transcribed at a gene's 5′ or 3′ end; Tx, strong transcription; TxWk, weak transcription; EnhG, genic enhancer; Enh, enhancer; ZNF/Rpts, ZNF genes and repeats; Het, heterochromatin; TssBiv, bivalent/poised TSS; BivFlnk, flanking bivalent TSS/enhancer; EnhBiv, bivalent enhancer. (d) Decision tree for predicting the direction of the effects of eQTMs. Each subplot shows the distributions for positive (blue) and negative (red) associations for that subset of the data. Dashed vertical lines correspond to the optimal split used by the algorithm. The boxes in the leaves show the number of positive and negative effects in each of the leaves. (e) Receiver operator characteristic curve showing the performance of the decision tree. AUC, area under the receiver operating curve.
generating RNA-seq data for 2,101 of 3,841 individuals in our study. Using a conservative approach that maximally accounts for potential biases (Online Methods), we identified 12,809 unique CpGs that correlated with 3,842 unique genes in cis (CpG-level FDR < 0.05). eQTMs were enriched for mapping to active regions, for example, in and around active transcription start sites (TSSs) (3-fold enrichment, P = 1.8 × 10 −91 ) and enhancers (2-fold enrichment, P = 1.1 × 10 −139 ; Fig. 2b ). The majority of eQTMs showed the canonical negative correlation with transcriptional activity (69.2%), but a substantial minority of correlations were positive (30.8%), in line with recent evidence that DNA methylation does not always negatively correlate with gene expression 14 . As expected, negatively correlated eQTMs were enriched in active regions such as active TSSs (3.7-fold enrichment, P = 9.5 × 10 −202 ). Positive correlations primarily occurred in repressed regions (for example, Polycomb-repressed regions, 3.4-fold enrichment, P = 5.8 × 10 −103 ) ( Supplementary Fig. 4) . The sharp contrast between positively and negatively associated eQTMs enabled us to predict the direction of the correlation. A decision tree trained on the strongest eQTMs (those with FDR < 9.7 × 10 −6 , n = 5,137), using data on histone marks and distance relative to genes, could predict the direction with an area under the curve of 0.83 (95% confidence interval, 0.78-0.87) (Fig. 2d,e) .
We next ascertained whether trans-meQTLs are biologically informative, as previous trans-eQTL mapping studies demonstrated that identifying trans expression effects provides a powerful tool to uncover and understand the downstream biological effects of diseaseassociated SNPs 3, 15, 16 . We focused on 6,111 SNPs that were previously associated with complex traits and diseases ('trait-associated SNPs'; Online Methods and Supplementary Table 3) . We observed that one-third of these trait-associated SNPs (1,907 SNPs; 31.2%) affected methylation in trans at 10,141 CpG sites, totaling 27,816 SNP-CpG combinations (FDR < 0.05, P < 2.6 × 10 −7 ; Fig. 3a ). This represents a fivefold increase in the number of CpG sites affected as compared with a previous trans-meQTL mapping study 17 . We evaluated whether the trait-associated SNPs themselves were likely to underlie the trans effects or whether the associations could be attributed to other SNPs in moderate linkage disequilibrium (LD). Of the 1,907 trait-associated SNPs with trans effects, 1,538 (87.2%) were in strong LD with the top SNP (r 2 > 0.8), indicating that the GWAS SNPs are indeed the driving force behind many of the trans-meQTLs. Of note, because of the sparse coverage of the Illumina HumanMethylation450 BeadChip, the true number of CpGs in the genome that are altered by these trait-associated SNPs will be substantially higher.
To validate our trans-meQTLs, we performed a replication analysis in a set of 1,748 lymphocyte samples 17 . Of the 18,764 overlapping trans-meQTLs, 94.9% had a consistent allelic direction in the replication data ( Fig. 1e and Supplementary Table 4) . This indicates that the identified trans-meQTLs are robust and are not caused by differences in cell type composition. Further analysis of SNPs known to influence blood cell composition 18, 19 showed no or only few effects in trans and alternative adjustments of the methylation data corroborated the stability of the trans effects, with both approaches indicating a limited influence of cell type composition (Supplementary Tables 5-7 and Supplementary Note).
After identifying trans-meQTLs, we assessed whether their respective SNPs also affected the expression of the genes associated with the CpGs in trans. By overlaying the trans-meQTLs and cis-eQTMs, we could link 436 SNPs to 850 genes, totaling 2,889 SNP-gene pairs. We found significant associations (trans-eQTLs; FDR < 0.05) for 8.4% of these effects, and 91% of these effects showed the expected l e t t e r S direction of effect given the directions of effect for the trans-meQTL and cis-eQTM (Supplementary Table 8 ).
In contrast to cis-meQTL CpGs, trans-meQTL CpGs showed substantial functional enrichment: they were enriched around TSSs and depleted in heterochromatin (Fig. 2c) and were strongly enriched for being an eQTM (1,913 CpGs (18.9%), 5.2-fold enrichment, P = 2.3 × 10 −101 ). Among the 1,907 trait-associated SNPs that made up the trans-meQTLs, there was an over-representation of GWAS-identified SNPs associated with immune-and cancer-related traits (Fig. 3a) . The large majority of trans-meQTLs were interchromosomal (93%; 9,429 CpG-SNP pairs) and included 12 trans-meQTL SNPs (yielding 3,616 unique CpG-SNP pairs) that each showed 
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Trans-eQTL We subsequently studied the nature of these trans-meQTLs. Using high-resolution Hi-C data 20 , we identified 720 SNP-CpG pairs (including 402 CpG sites and 172 SNPs) among the trans-meQTLs that overlapped with an interchromosomal contact, which is 2.9-fold more than expected by chance (P = 3.7 × 10 −126 ; Fig. 3a,b) . The enrichment for Hi-C interchromosomal contacts remained after removing SNPs that were responsible for trans bands (P = 1.7 × 10 −61 ). Hence, interchromosomal contacts may produce associations between SNPs and CpGs in trans. To characterize the 720 SNP-CpG pairs overlapping with interchromosomal contacts, we examined motif enrichment using three motif enrichment analysis tools (HOMER, PWMEnrich and DEEPbind) 21, 22 . These analyses showed that the 402 CpG sites involved frequently overlapped with binding sites for CTCF, RAD21 and SMC3 (P = 2.3 × 10 −5 , P = 3.5 × 10 −5 and P = 5.1 × 10 −5 , respectively), factors known to regulate chromatin architecture 23, 24 . An analysis of ChIP-seq data on CTCF binding confirmed this finding (1.8-fold enrichment, P = 5.2 × 10 −7 ).
We next tested whether the trans-meQTLs reflected the effect of differential transcription factor binding for transcription factors that mapped close to the SNPs. The rationale for this hypothesis is that binding of transcription factors has been linked to changes in local DNA methylation, primarily loss of methylation upon transcription factor binding and gain of methylation after loss of transcription factor occupancy 7, 8 . This model suggests that trans-meQTLs may be attributed to SNPs affecting the expression of a transcription factor in cis and that the SNP allele preferentially has a unidirectional effect on DNA methylation. In line with this prediction, we observed that, if a SNP was associated with multiple CpG sites in trans (at least 10, n = 305), the direction of the association of the SNP was consistently skewed toward either increased or decreased DNA methylation. On average, 76% of the CpGs for each trans-meQTL SNP displayed the same direction of effect (50% expected, P = 1 × 10 −111 ; Fig. 4a) . A significant skew in the direction of the allelic effect was present for 59.7% of the 305 individual SNPs with at least 10 trans-meQTL effects, and this proportion increased to 95.2% for the 104 SNPs with at least 50 trans-meQTL effects (binomial P < 0.05), suggesting that differential transcription factor binding might explain a substantial fraction of trans-meQTLs.
To explore this mechanism further, we combined ChIP-seq data on transcription factor binding at CpGs with the expression effects in cis of SNPs to directly examine the involvement of transcription factors in mediating trans-meQTLs. Among the trait-associated SNPs influencing at least 10 CpGs in trans (n = 305), we identified 13 trans-meQTL SNPs with strong support for a role of transcription factors (Fig. 4a) .
The most striking example was a locus on chromosome 4 ( Fig. 4b) , where two SNPs (rs3774937 and rs3774959; in strong LD) were associated with ulcerative colitis 25 . The top SNP, rs3774937, was associated with differential DNA methylation at 413 CpG sites across the genome, 92% of which showed the same direction of effect-that is, lower methylation-associated with the minor allele (binomial P = 2.72 × 10 −69 ). Of the 380 CpG sites with lower methylation, 147 (38.7%) overlapped with a nuclear factor (NF)-κB transcription factor binding site (2.75-fold enrichment, P = 5.3 × 10 −32 ), as derived from Encyclopedia of DNA Elements (ENCODE) NF-κB ChIP-seq data in blood cell types (Fig. 4c) . Three motif enrichment analysis tools (HOMER, PWMEnrich and DEEPbind) 21, 22 corroborated the (Fig. 4c) . Notably, SNP rs3774937 is located in the first intron of NFKB1, and we found that the minor allele was associated with higher NFKB1 expression (Fig. 4a) . Of the 413 CpGs in trans, 64 were eQTMs and showed a coherent gene network (Fig. 4d) that was enriched for immunological processes related to NFKB1 function 26 (Fig. 4e) . Taken together, these results support the idea that the minor allele of rs3774937, which is associated with increased risk of ulcerative colitis, decreases DNA methylation in trans by increasing NFKB1 expression in cis.
The same analysis approach indicated that the 779 methylation effects of rs8060686 in trans (associated with various phenotypes, including metabolic syndrome 27 and coronary heart disease 28 ) were mediated by altered CTCF binding, which mapped 315 kb from the trans-meQTL SNP. We observed strong CTCF ChIP-seq enrichment (603 of the 779 CpGs in trans overlapping with CTCF binding; P = 1.6 × 10 −232 ) and enrichment for CTCF motifs (Fig. 5) . Of these trans CpGs, only 13 were observed previously in lymphocytes 17 . Hence, the minor allele of rs8060686 increased DNA methylation in trans, which could be attributed to lower CTCF gene expression in cis.
We found another example of this phenomenon: 228 trans-meQTL effects of four SNPs on chromosome 10, mapping near NKX2-3 and implicated in inflammatory bowel disease 25 , were strongly enriched for NKX2 transcription factor motifs and associated with NKX2-3 expression. Again, a negative correlation was observed, in which the minor allele of rs11190140 decreased DNA methylation in trans at NKX2-3-binding sites and increased NKX2-3 gene expression in cis (Supplementary Fig. 5) .
A height-associated locus 29 harboring four SNPs and associated with 267 trans CpGs implicated a role for ZBTB38 in mediating transmeQTL effects (Supplementary Fig. 6 ). In contrast to the aforementioned transcription factors, which are all transcriptional activators, ZBTB38 is a transcriptional repressor 30, 31 and its expression was positively correlated with methylation in trans, in line with our observation that eQTMs in repressed regions are enriched for positive correlations. Finally, the methylation effects in trans of rs7216064 (64 trans CpGs), associated with lung carcinoma 32 , preferentially occurred at regions binding CTCF, while the SNP was located in the BPTF gene, which encodes a protein known to occupy CTCF-binding sites 33 (Supplementary Fig. 7) .
The possibility of linking trans-meQTL effects to an association with transcription factor expression in cis and concomitant differential methylation in trans at the respective binding site for the transcription factor is limited to transcription factors for which ChIP-seq data or motif information is available. To make inferences on transcription factors for which such data are not yet available, we ascertained whether trans-meQTL SNPs were more often associated with transcription factor gene expression in cis as compared with SNPs without a trans-meQTL effect. We observed that 13.1% of the trait-associated SNPs that produced trans-meQTLs also affected transcription factor gene expression in cis, whereas only 4.5% of the trait-associated SNPs without a trans-meQTL affected transcription factor gene expression in cis (Fisher's exact P = 6.6 × 10 −13 ).
Here we report that one-third of known disease-and trait-associated SNPs have downstream effects on methylation in trans and often are associated with multiple regions across the genome. Our data suggest that the biological mechanism underlying trans-meQTLs commonly involves a local effect on the expression of a nearby transcription factor that influences DNA methylation at the distal binding sites of that particular transcription factor. The direction of downstream methylation effects is remarkably consistent for each SNP and indicates that decreased DNA methylation is a signature of increased binding of transcriptional activators. As such, our study identifies the previously unrecognized functional consequences of diseaseassociated variants in noncoding regions. These can be viewed online (see URLs) and will provide leads for experimental follow-up. 
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Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Accession codes.
All results can be queried using our dedicated QTL browser (see URLs). Raw data were submitted to the European Genomephenome Archive (EGA) under accession EGAS00001001077.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
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oNLINe MeTHoDS
Cohort descriptions. The five cohorts used in our study are described briefly below. The number of samples per cohort and references to full cohort descriptions can be found in Supplementary Table 1. CODAM. The Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) 10 consists of a selection of 547 subjects from a larger populationbased cohort 34 . Inclusion of subjects into CODAM was based on a moderately increased risk of developing cardiometabolic diseases, such as type 2 diabetes and/or cardiovascular disease. Subjects were included if they were of European ancestry and over 40 years of age and additionally met at least one of the following criteria: increased body mass index (BMI; >25), a positive family history for type 2 diabetes, a history of gestational diabetes and/or glycosuria, or use of antihypertensive medication.
LifeLines-DEEP. The LifeLines-DEEP (LLD) cohort 9 is a subcohort of the LifeLines cohort 35 . LifeLines is a multidisciplinary prospective populationbased cohort study examining the health and health-related behaviors of 167,729 individuals living in the northern parts of the Netherlands using a unique three-generation design. It employs a broad range of investigative procedures assessing biomedical, sociodemographic, behavioral, physical and psychological factors contributing to health and disease in the general population. A subset of 1,500 LifeLines participants also take part in LLD 9 . For these participants, additional molecular data are generated, allowing for a more thorough investigation of the association between genetic and phenotypic variation.
LLS. The aim of the Leiden Longevity Study (LLS) 11 is to identify genetic factors influencing longevity and examine their interaction with the environment as a means to develop interventions to increase health at older ages. To this end, long-lived siblings of European descent were recruited together with their offspring and their offspring's partners, on the condition that at least two long-lived siblings were alive at the time of ascertainment. For men, the age criterion was 89 years or older; for women, the age criterion was 91 years or older. These criteria led to the ascertainment of 944 long-lived siblings from 421 families, together with 1,671 of their offspring and 744 partners.
NTR. The Netherlands Twin Register (NTR) 12, 36, 37 was established in 1987 to study the extent to which genetic and environmental influences cause phenotypic differences between individuals. To this end, data from twins and their families (nearly 200,000 participants) from all over the Netherlands are collected, with a focus on health, lifestyle, personality, brain development, cognition, mental health and aging.
RS. The Rotterdam Study 13 is a single-center, prospective population-based cohort study conducted in Rotterdam, the Netherlands. Subjects were included in different phases, with a total of 14,926 men and women aged 45 years and over included as of late 2008. The main objective of the Rotterdam Study is to investigate the prevalence and incidence of and risk factors for chronic diseases to contribute to better prevention and treatment of such diseases in the elderly.
Genotype data. Data generation. Genotype data was generated for each cohort individually. Details on the methods used can be found in the individual papers (CODAM 34 ; LLD 9 ; LLS 38 ; NTR 12 ; RS 13 ).
Imputation and QC. For each cohort separately, the genotype data were harmonized toward the Genome of the Netherlands 39 (GoNL) using Genotype Hamonizer 40 and subsequently imputed per cohort using Impute2 (ref. 41) using GoNL 42 reference panel 42 (v5) . Quality control was also performed per cohort. We removed SNPs based on imputation info-score (<0.5), HWE (P < 10 −4 ), call rate (<95%) and minor allele frequency (>0.05), resulting in 5,206,562 SNPs that passed quality control in each of the data sets.
Methylation data. Data generation.
For the generation of genome-wide DNA methylation data, 500 ng of genomic DNA was bisulfite modified using the EZ DNA Methylation kit (Zymo Research) and hybridized on Illumina 450K arrays according to the manufacturer's protocols. The original IDAT files were generated by the Illumina iScan BeadChip scanner. We collected methylation data for a total of 3,841 samples. Data was generated by the Human Genotyping facility (HugeF) of ErasmusMC, The Netherlands (see URLs).
Probe remapping and selection. We remapped the 450K probes to the human genome reference (hg19) to correct for inaccurate mappings of probes and identify probes that mapped to multiple locations on the genome. Details on this procedure can be found in Bonder et al. 43 . Next, we removed probes with a known SNP (GoNL, MAF > 0.01) at the single base extension (SBE) site or CpG site. Lastly, we removed all probes on the sex chromosomes, leaving 405,709 high quality methylation probes for the analyses.
Normalization and QC. Methylation data was processed using a custom pipeline based on the pipeline developed by Tost & Toulemat 44 . First, we used methylumi to extract the data from the raw IDAT files. Next, we removed incorrectly mapped probes and checked for outlying samples using the first two principal components (PCs) obtained using principal component analysis (PCA). None of the samples failed our quality control checks, indicating high quality data. Following quality control, we performed background correction and probe type normalization as implemented in DASEN 45 . Normalization was performed per cohort, followed by quantile normalization on the combined data to normalize the differences per cohort. We used mix-up mapper 46 to identify sample mix-ups between genotype and DNA methylation data, detecting and correcting 193 mix-ups. Lastly, in order to correct for known and unknown confounding sources of variation in the methylation data and increase statistical power, we removed the first components which were not affected by genetic information (22 PCs) from the methylation data using methodology we have successfully used in trans-eQTL 3, 47 and meQTL analyses 43 .
RNA sequencing. Total RNA from whole blood was depleted of globin transcripts using the Ambion GLOBIN clear kit and subsequently processed for sequencing using the Illumina TruSeq version 2 library preparation kit. Pairedend sequencing of 2 × 50-bp reads was performed using the Illumina HiSeq 2000 platform, pooling ten samples per lane. Finally, read sets were generated for each sample using CASAVA, retaining only reads passing the Illumina Chastity Filter for further processing. Data were generated by the Human Genotyping facility (HugeF) of ErasmusMC, the Netherlands (see URLs).
Initial quality control was performed using FastQC v0.10.1 (see URLs), removal of adaptors was performed using cutadapt 48 (v1.1) and Sickle v1.2 (see URLs) was used to trim low-quality ends from the reads (min length 25, min quality 20). Sequencing reads were mapped to the human genome (hg19) using STAR 49 v2.3.125. Gene expression quantification was performed by HTseq-count. The gene definitions used for quantification were based on Ensembl version 71, with the extension that regions with overlapping exons were treated as separate genes and reads mapping within these overlapping parts did not count toward expression of the normal genes. Expression data on the gene level were first normalized using trimmed mean of M values 50 . Then, expression values were log 2 transformed, and gene and sample means were centered to zero. To correct for batch effects, principalcomponent analysis (PCA) was run on the sample correlation matrix and the first 25 principal components were removed using methodology that we have used before 3, 47 ; details are provided in Zhernakova et al. 51 .
Cis-meQTL mapping. To determine the effect of nearby genetic variation on methylation levels (cis-meQTL, here defined as the relationship between a CpG and a SNP no further than 250 kb apart), we performed cis-meQTL mapping using 3,841 samples for which both genotype data and methylation data were available. To this end, we calculated the Spearman rank correlation for each cohort, followed by meta-analysis using a weighted z method described previously 3 . To detect all possible independent SNPs regulating methylation at a single CpG site, we regressed out all primary cis-meQTL effects and then performed cis-meQTL mapping for the same CpG site to find secondary cis-meQTLs. We repeated this in a stepwise fashion until no more independent cis-meQTLs were found.
To filter out potential false positive cis-meQTLs caused by SNPs affecting the binding of a probe on the array, we filtered the cis-meQTL effects by removing any CpG-SNP pairs for which the SNP was located in the probe. In addition, all other CpG-SNP pairs for which the SNP was outside the probe but in LD (r 2 > 0.2 or D′ > 0.2) with a SNP inside the probe were also removed. We tested for LD between SNPs in probes and in surrounding cis areas in the individual genotype data sets, as well as in GoNL v5, to be as strict as possible in marking a QTL as a true positive.
To correct for multiple testing, we empirically controlled the FDR at 5%. For this, we compared the distribution of observed P values to the distribution obtained from performing the analysis on permuted data. Permutation was performed by shuffling the sample identifiers of one data set, thereby breaking the link between, for example, the genotype data and the methylation or expression data. We repeated this procedure ten times to obtain a stable distribution of P values under the null distribution. The FDR was determined by only selecting the strongest effect for each CpG 3 in both the real analysis and the permutations (probe-level FDR < 5%).
Cis-eQTL mapping. For a set of 2,116 BIOS samples we had also generated RNA-seq data. We used this data to identify cis-eQTLs. Cis-eQTL mapping was performed using the same method as cis-meQTL mapping. Details on these eQTLs are described in a separate paper 51 .
Expression quantitative trait methylation analysis. To identify associations between methylation levels and the expression levels of nearby genes (cis-eQTMs), we first corrected our expression and methylation data for batch effects and covariates by regressing out the principal components and regressing out the identified cis-meQTLs and cis-eQTLs, to ensure that the associations identified between CpG sites and gene expression levels were not due to shared genetic effects. We mapped the eQTMs in a window of 250 kb around the TSS of a transcript. Further statistical analysis was identical to that for cis-meQTL mapping. For this analysis, we were able to use a total of 2,101 samples for which both genetic, methylation and gene expression data were available. To correct for multiple testing, we controlled the FDR at 5%; the FDR was determined by only selecting the strongest effect for each CpG 3 in both the real analysis and the permutations.
Trans-meQTL mapping. To identify the effects of distal genetic variation on methylation (trans-meQTLs), we used the same 3,841 samples that we had used for cis-meQTL mapping. To focus our analysis and limit the multipletesting burden, we restricted our analysis to SNPs that have previously been found to be significantly correlated with traits and diseases. We extracted these SNPs from the NHGRI GWAS catalog and also used recent GWAS not yet in the NHGRI GWAS catalog and studies on the Immunochip and Metabochip platforms that are not included in the NHGRI GWAS catalog. We compiled this list of SNPs in December 2014. For each SNP, we only investigated CpG sites that mapped at least 5 Mb from the SNP or on other chromosomes. Before mapping trans-meQTLs, we regressed out the identified cis-meQTLs to increase the statistical power of trans-meQTL detection (as done previously for trans-eQTLs 3 ) and to avoid designating an association as trans that might be due to long-range LD (for example, within the human leukocyte antigen (HLA) region). To ascertain the stability of the trans-meQTLs, we also performed trans mapping using uncorrected methylation data and data corrected for cell type proportions. In addition, we performed meQTL mapping on SNPs known to influence cell type proportions in blood 18, 19 .
To filter out potential false positive trans-meQTLs due to cross-hybridization of the probe, we remapped the methylation probes with very relaxed settings identical to those used in Westra et al. 3 , with the difference that we only accepted mappings if the last bases of the probe including the SBE site were accurately mapped to the alternative location. If the probe mapped within our minimal trans window, 5 Mb from the SNP, we removed the effect as being a false positive trans-meQTL.
We controlled the FDR at 5%, identical to in the aforementioned cis-meQTL analysis.
Trans-eQTL mapping. To check whether trans-meQTL effects also showed in gene expression levels, we annotated the CpGs with a trans-meQTL to genes using our eQTMs. Using the 2,101 samples for which both genotype and gene expression data were available, we performed trans-eQTL mapping, associating SNPs known to be associated with DNA methylation in trans with their corresponding eQTM genes.
Annotation and enrichment tests. Annotation of CpG sites was performed using Ensembl 52 (v70), the UCSC Genome Browser 53 and data from the Epigenomics Roadmap project 54 . We used Epigenomics Roadmap annotation for the SBE site of the methylation site using 27 blood cell types. We used both the histone mark information and the chromatin marks in blood-related cell types only, as generated by the Epigenomics Roadmap project. Summarizing the information over the 27 blood cell types was carried out by counting the presence of histone marks in all the cell types and scaling the abundance: that is, the score would be 1 if a mark is bound in all cell types, whereas the score would be 0 if it is present in none of the blood cell types.
To calculate enrichment of meQTLs or eQTMs for any particular genomic context, we used logistic regression because this allowed us to account for covariates such as CpG methylation variation. For cis-meQTLs, we used the variability in DNA methylation, the number of SNPs tested and the distance to the nearest SNP for each CpG as covariates. For all other analyses, we used only the variability in DNA methylation as a covariate.
We used transcription factor ChIP-seq data from the ENCODE project for blood-related cell lines (narrow-peak data). We overlapped CpG locations with ChIP-seq signals and performed a Fisher's exact test to determine whether the trans-meQTL probes associated with a SNP overlapped a ChIP-seq region more often than other trans-meQTL probes.
Enrichment of known sequence motifs among trans-CpGs was assessed using the PWMEnrich package in R, HOMER 55 and DEEPbind 22 . For PWMEnrich, the 100-bp sequence around each interrogated CpG site was used, and as a background set we used the top CpGs from the 50 permutations used to determine the FDR threshold of the trans-meQTLs. For HOMER, the default settings for the identification of motif enrichment were used, and the same CpG sites derived from the permutations were used as background. For DEEPbind, we used both the permutation background as described for HOMER and the permutation background as described for PWMEnrich.
Using data published by Rao et al. 20 , we were able to intersect the transmeQTLs with information about the 3D structure of the human genome using combined Hi-C data for both inter-and intrachromosomal data at 1 kb and the quality threshold of E30 in the GM12878 LCL. Both the trans-meQTL SNPs and trans-meQTL probes were put in the relevant 1-kb blocks, and for these blocks we looked up the chromosomal contact value in the measurements by Rao et al. Surrounding the trans-meQTL SNPs, we used an LD window that spanned maximally 250 kb from the trans-meQTL SNP and had a minimal r 2 value of 0.8. If a Hi-C contact was indicated between a SNP block and a CpG site, we flagged the region as positive for Hi-C contacts. As background, we used the combinations found in our 50 permutated trans-meQTL analyses, taking for each permutation the top trans-meQTLs that were similar in size to those from the real analysis.
Prediction of eQTM direction. We predicted the direction of eQTM effects using both a decision tree and a naive Bayes model (as implemented by Rapidminer 56 v6.3). We built the models on the strongest eQTMs (FDR < 9.73 × 10 −6 ). For the decision tree, we used a standard cross-validation setup with 20 folds. For the naive Bayesian model, we used double-loop cross-validation: performance was evaluated in the outer loop using 20-fold cross-validation, while feature selection (using both backward elimination and forward selection) took place in the inner loop using tenfold cross-validation. Details about double-loop cross-validation can be found in Ronde et al. 57 . During the training of the model, we balanced the two classes, making sure we had an equal number of positively correlating and negatively correlating CpG-gene combinations, by randomly sampling a subset of the over-represented negatively correlating CpG-gene combination group. We chose to do so to circumvent labeling al eQTMs as negative, as this is the class to which the majority of the eQTMs belonged.
In the models, we used CpG-centric annotations: overlap with Epigenomics Roadmap chromatin states, histone marks and relationships between the histone marks, GC content surrounding the CpG site and relative locations from the CpG site to the transcript.
DEPICT. To investigate whether there was biological coherence in the trans-meQTLs identified for the NFKB1 locus, we performed gene set enrichment analysis for the genes near the trans-CpG sites of the ulcerative colitis genetic risk factor (which maps in the NFKB1 locus). To do so, we adapted DEPICT 26 , a pathway enrichment analysis method that we originally developed for GWAS. Instead of defining loci with genes by using the top associated SNPs (as is done when analyzing GWAS data), we used the eQTM information to empirically link trans-CpGs to genes (that map close to the CpGs).
Within DEPICT gene set enrichment, significance is determined by using a background set of genes. As background in the adapted DEPICT enrichment analyses, we matched our background to the results from the actual transmeQTL and eQTM analyses: matching was performed by generating a set of background CpGs (and corresponding correlating eQTM genes), by selecting an equal number of CpGs for which we had found trans-meQTL effects with SNPs that map outside the NFKB1 locus. By doing so, we ensured that the characteristics of these background CpGs were the same as those for the real NFKB1 trans-meQTL CpGs, both in terms of CpG variance and the requirement that they also show a significant correlation with expression levels of genes close to the CpG (that is, a cis-eQTM), ensuring that the corresponding input genes for DEPICT had the same expression variation distribution in the actual NFKB1 analysis and in the background. Subsequent pathway enrichment analysis was conducted as described before 26 , and significance was determined by controlling the FDR at 5%.
